Allarity Therapeutics (ALLR) vs Neuphoria Therapeutics (NEUP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Allarity Therapeutics (ALLR) has outperformed Neuphoria Therapeutics (NEUP) over the past year, losing 25.9% versus a loss of 47.3%. Neuphoria Therapeutics is the larger company by market cap ($12.7 million vs $12.6 million), about 1.0 times the size. Neuphoria Therapeutics converts more of its revenue into profit, with a net margin of -1145.7% versus -3509.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | NEUP |
|---|---|---|
| Share price | $0.785 | $2.35 |
| Market cap | $12.56M | $12.72M |
| 1-day change | -9.25% | +1.29% |
| YTD return | -27.31% | -39.43% |
| 1-year return | -25.94% | -47.31% |
| EPS (TTM) | $-0.79 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $320.00K | $1.17M |
| Revenue growth (YoY) | — | -92.50% |
| Net income (latest FY) | $-11.23M | $-13.45M |
| Operating margin | -3939.06% | -1401.09% |
| Net margin | -3509.69% | -1145.66% |
| 52-week high | $1.84 | $5.53 |
| 52-week low | $0.769 | $2.26 |
| Distance from 52-week high | -57.34% | -57.50% |
| Analyst consensus | none | none |
| Avg. price target upside | +1301.27% | — |
| Average volume | 131.74K | 26.53K |
| Shares outstanding | 16.00M | 5.41M |
| Employees | 7 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLR has outperformed NEUP by 21.4 percentage points over the past year.
- Neuphoria Therapeutics is more profitable, keeping -1145.7 cents of every revenue dollar as net income versus -3509.7 cents for Allarity Therapeutics.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Neuphoria Therapeutics
NEUP stock →Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
ALLR vs NEUP FAQ
Which is bigger, Allarity Therapeutics or Neuphoria Therapeutics?
Neuphoria Therapeutics (NEUP) is larger, with a market capitalization of $12.72M compared with $12.56M for Allarity Therapeutics (ALLR).
Which stock has performed better over the past year, ALLR or NEUP?
ALLR returned -25.94% over the past 12 months, compared with -47.31% for NEUP (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and Neuphoria Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.